Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
01/22/21 3:49 PM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jan 11 2021
Summary ToggleAdverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
- Jan 7 2021
Summary ToggleAdverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
- Jan 5 2021
Summary ToggleAdverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
- Dec 14 2020
Summary ToggleAdverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
There are currently no events to display.